• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment.

作者信息

Rüschoff Jan H, Gradhand Elise, Kahraman Abdullah, Rees Helen, Ferguson Jane L, Curioni-Fontecedro Alessandra, Zoche Martin, Moch Holger, Vrugt Bart

机构信息

University Hospital Zurich, Zurich, Switzerland.

Dr Senckenberg Institute of Pathology, University Hospital Frankfurt, Germany.

出版信息

JCO Precis Oncol. 2019 Jul 11;3. doi: 10.1200/PO.19.00048. eCollection 2019.

DOI:10.1200/PO.19.00048
PMID:32914035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7446511/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/5215cfaa2981/PO.19.00048f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/f091b8c5c2a1/PO.19.00048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/0c91cc73b9cb/PO.19.00048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/162565b8ca3d/PO.19.00048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/5215cfaa2981/PO.19.00048f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/f091b8c5c2a1/PO.19.00048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/0c91cc73b9cb/PO.19.00048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/162565b8ca3d/PO.19.00048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1604/7446511/5215cfaa2981/PO.19.00048f4.jpg

相似文献

1
Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment.经色瑞替尼治疗后出现显著反应的重排性恶性腹膜间皮瘤
JCO Precis Oncol. 2019 Jul 11;3. doi: 10.1200/PO.19.00048. eCollection 2019.
2
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.色瑞替尼在间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者中的活性与安全性（ASCEND-1）：多中心、开放标签、1期试验的更新结果
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
3
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.塞瑞替尼与化疗用于既往接受过化疗和克唑替尼治疗的间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者（ASCEND-5）：一项随机、对照、开放标签、III 期临床试验。
Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.
4
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
5
Clinical Efficacy of Alectinib in Patients with -Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.阿来替尼对色瑞替尼治疗失败的间变性淋巴瘤激酶重排非小细胞肺癌患者的临床疗效
Anticancer Res. 2017 Nov;37(11):6477-6480. doi: 10.21873/anticanres.12103.
6
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.一线塞瑞替尼与铂类化疗用于晚期ALK 重排非小细胞肺癌（ASCEND-4）：一项随机、开放标签、III 期研究。
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
7
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.克唑替尼治疗后化疗和克唑替尼治疗的 ALK 重排非小细胞肺癌患者的塞瑞替尼全身和颅内活性的多中心 II 期研究：ASCEND-2 的结果。
J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18.
8
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).ASCEND-8：一项随机、1 期研究，评估塞瑞替尼 450mg 或 600mg 随低脂餐服用与 750mg 空腹服用在间变性淋巴瘤激酶（ALK）重排转移性非小细胞肺癌（NSCLC）患者中的疗效。
J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.
9
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.在一名既往接受过克唑替尼和色瑞替尼治疗的ALK重排非小细胞肺癌患者中鉴定出一种新型的T1151K ALK突变。
Lung Cancer. 2017 Aug;110:32-34. doi: 10.1016/j.lungcan.2017.05.018. Epub 2017 May 22.
10
A case of -rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib.一例ALK重排的非小细胞肺癌，在对阿来替尼产生耐药后对色瑞替尼有反应。
Oncotarget. 2018 May 1;9(33):23315-23319. doi: 10.18632/oncotarget.25143.

引用本文的文献

1
Improving global access to genomic profiling in rare pediatric cancers.改善全球范围内罕见儿科癌症的基因组分析可及性。
Clin Cancer Res. 2025 May 20. doi: 10.1158/1078-0432.CCR-24-3910.
2
Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib.病例报告：克唑替尼治疗间变性淋巴瘤激酶受体酪氨酸激酶基因融合突变的恶性胸膜间皮瘤。
J Int Med Res. 2024 Nov;52(11):3000605241287320. doi: 10.1177/03000605241287320.
3
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.

本文引用的文献

1
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.超越微卫星检测：肿瘤突变负荷评估可识别可能对免疫检查点抑制有反应的结直肠癌亚组。
J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.
2
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.鉴定恶性腹膜间皮瘤中的 ALK 重排。
JAMA Oncol. 2018 Feb 1;4(2):235-238. doi: 10.1001/jamaoncol.2017.2918.
3
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
弥漫性胸膜间皮瘤患者靶向治疗方法的过去、现在与未来
J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.140. Epub 2023 May 30.
4
Targeted Therapy in Mesotheliomas: Uphill All the Way.间皮瘤的靶向治疗：一路艰难前行。
Cancers (Basel). 2024 May 22;16(11):1971. doi: 10.3390/cancers16111971.
5
Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.临床下一代测序在间皮瘤中的应用：大海捞针
Cancers (Basel). 2023 Dec 6;15(24):5716. doi: 10.3390/cancers15245716.
6
ALK fusions in the pan-cancer setting: another tumor-agnostic target?泛癌背景下的ALK融合：另一个不依赖肿瘤类型的靶点？
NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x.
7
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.一名卵巢恶性间皮瘤患者中新型STRN-ALK与NBEA-ALK双融合的共存：病例报告与文献复习
Front Oncol. 2023 Apr 21;13:1156329. doi: 10.3389/fonc.2023.1156329. eCollection 2023.
8
Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.色瑞替尼对伴有STRN-ALK融合的转移性乳头状甲状腺癌有显著反应：一例报告
Front Oncol. 2022 Nov 9;12:1009076. doi: 10.3389/fonc.2022.1009076. eCollection 2022.
9
Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.腹膜间皮瘤的分子途径：新见解的简要综述
Front Oncol. 2022 Feb 10;12:823839. doi: 10.3389/fonc.2022.823839. eCollection 2022.
10
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.恶性胸膜间皮瘤的新纪元：治疗选择的最新进展。
J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5.
克唑替尼靶向间变性淋巴瘤激酶治疗儿童间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤：儿童肿瘤协作组研究
J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.
4
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.克唑替尼靶向基因ROS1/ALK/MET在恶性间皮瘤中的荧光原位杂交分析
J Thorac Oncol. 2017 Aug;12(8):e116-e118. doi: 10.1016/j.jtho.2017.03.015.
5
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.美国间皮瘤：一项基于监测、流行病学及最终结果（SEER）-医疗保险的治疗模式与总生存情况调查。
Clin Epidemiol. 2016 Oct 26;8:743-750. doi: 10.2147/CLEP.S105396. eCollection 2016.
6
Distinctive clinical characteristics of malignant mesothelioma in young patients.年轻患者恶性间皮瘤的独特临床特征。
Oncotarget. 2015 Jun 30;6(18):16766-73. doi: 10.18632/oncotarget.4414.
7
Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.儿童恶性腹膜间皮瘤中的间变性淋巴瘤激酶（ALK）易位：一种新型 ALK 相关肿瘤谱的病例报告。
Histopathology. 2016 Mar;68(4):603-7. doi: 10.1111/his.12779. Epub 2015 Sep 2.
8
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.影响 35 例恶性腹膜间皮瘤患者生存的预后因素。
Neoplasma. 2014;61(4):433-8. doi: 10.4149/neo_2014_053.
9
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.恶性腹膜间皮瘤：预后因素与肿瘤学结局分析
Ann Surg Oncol. 2014 Apr;21(4):1159-65. doi: 10.1245/s10434-013-3358-y. Epub 2013 Dec 10.
10
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.基于大规模平行DNA测序的临床癌症基因组分析检测方法的开发与验证
Nat Biotechnol. 2013 Nov;31(11):1023-31. doi: 10.1038/nbt.2696. Epub 2013 Oct 20.